GlassScriptPhysician profile
Kevin Braat
NPI 1871595462
$5,072.41
in general payments reported to CMS, 2019-2025
37 companies · $822 in 2025
The $822 reported for 2025 was more than what 75% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $1,293 · 2021: $585 · 2022: $557 · 2023: $513 · 2024: $808 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,143.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $860.37 | 2020 | |
| Glaxosmithkline, LLC. | $745.52 | 2019-2025 | Nucala |
| Optinose US, INC. | $513.06 | 2019-2025 | |
| Kaleo, INC. | $374.59 | 2019-2024 | Auvi-Q |
| Acclarent, INC | $255.76 | 2019-2023 | Acclarent Aera |
| Regeneron Healthcare Solutions, INC. | $229.73 | 2020-2025 | Dupixent |
| Genzyme Corporation | $219.31 | 2020-2025 | |
| Neurent Medical Limited | $185.31 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Takeda Pharmaceuticals U.S.A., INC. | $182.74 | 2021-2025 | Cuvitru, Eohilia |
| Amgen INC. | $149.89 | 2021-2025 | Tezspire |
| Grifols USA, LLC | $138.60 | 2022-2025 | Xembify |
| Genentech USA, INC. | $124.64 | 2023-2025 | Xolair |
| Incyte Corporation | $106.77 | 2022-2025 | Opzelura |
| Alk-Abello, INC | $97.16 | 2019-2022 | |
| Covis Pharma Gmbh | $95.81 | 2020-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $81.69 | 2023-2025 | Inspire |
| Intersect Ent, INC. | $72.93 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $69.11 | 2019-2025 | |
| Stryker Corporation | $65.51 | 2019-2021 | |
| Aerin Medical INC. | $55.09 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.84 | 2019 | |
| Arrinex, INC. | $46.70 | 2019 | |
| Aimmune Therapeutics, INC. | $45.29 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $37.69 | 2024-2025 | Ryaltris |
| Blueprint Medicines Corporation | $32.52 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $28.29 | 2025 | Neffy |
| Paratek Pharmaceuticals, INC. | $24.51 | 2025 | Xhance |
| Medtronic, INC. | $24.20 | 2024 | Propel |
| Leo Pharma INC. | $23.66 | 2022 | |
| Pfizer INC. | $19.83 | 2023 | |
| Octapharma USA, INC. | $19.53 | 2024 | Cutaquig |
| Csl Behring | $19.50 | 2024 | Hizentra |
| Merck Sharp & Dohme LLC | $17.34 | 2023 | |
| Jazz Pharmaceuticals INC. | $16.11 | 2021 | |
| Olympus America INC. | $15.76 | 2019 | |
| Smith+Nephew, INC. | $15.43 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Braat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.